Literature DB >> 8807204

Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.

T Sasagawa1, M Inoue, M Lehtinen, W Zhang, S E Gschmeissner, M A Hajibagheri, J Finch, L Crawford.   

Abstract

Serum samples from 36 cervical carcinoma patients, 33 patients with high-grade squamous intraepithelial lesions, and 31 cytologically normal women were tested by enzyme-linked immunosorbent assay (ELISA) using human papilloma virus type 6 (HPV 6) and HPV 16 virus-like particles as antigens. Forty serum specimens from 1-year-old children were used to assign cutoff points. When serum samples from the subjects infected with HPV 16 were tested in an HPV 16 ELISA detecting immunoglobulin A (IgA), IgG, and IgM binding, 61% showed IgA, 44% showed IgG, and 39% showed IgM reactivity. Of HPV 6- or 11- or HPV 18-infected subjects. fewer than 17% showed IgA or IgG responses and 33% showed IgM reactivity. In contrast, 13% showed IgA, 10% showed IgG, and 16% showed IgM reactivity in the HPV DNA-negative controls. The results suggest that the IgA and IgG responses are HPV 16 specific and the IgM response is cross-reactive to different HPV types. On the other hand, the serological responses to HPV 6 did not differ in the patient and control groups. The percentages of patients positive for both IgA and IgG antibodies were significantly higher in the groups with high-grade squamous intraepithelial lesions (12% [4 of 33]; P = 0.04) and cancer (17% [6 of 36]; P = 0.02) than in the healty women (0% [0 of 31]), and the percentages for either IgA or IgG were higher for the cancer group (47% [17 of 36]; P = 0.01) than in the normal group (19% [6 of 31]). Most sera positive for IgA and IgG in the patient groups showed higher titers than those in the normal group. All these results suggest that high IgA and IgG responses are good indicators for estimating HPV 16 infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807204      PMCID: PMC170358          DOI: 10.1128/cdli.3.4.403-410.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  38 in total

1.  The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop.

Authors: 
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

2.  Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts.

Authors:  S Ghim; N D Christensen; J W Kreider; A B Jenson
Journal:  Int J Cancer       Date:  1991-09-09       Impact factor: 7.396

3.  Prevalence of human papillomavirus types 11, 16 and 18 in cervical swabs. A study of 1362 pregnant women.

Authors:  U Hørding; A K Iversen; A Sebbelov; J E Bock; B Norrild
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1990 May-Jun       Impact factor: 2.435

4.  Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer.

Authors:  I Jochmus-Kudielka; A Schneider; R Braun; R Kimmig; U Koldovsky; K E Schneweis; K Seedorf; L Gissmann
Journal:  J Natl Cancer Inst       Date:  1989-11-15       Impact factor: 13.506

5.  Cervical/vaginal dysplasias of transgenic mice harbouring human papillomavirus type 16 E6-E7 genes.

Authors:  T Sasagawa; G Kondoh; M Inoue; M Yutsudo; A Hakura
Journal:  J Gen Virol       Date:  1994-11       Impact factor: 3.891

6.  Sequence variation in the capsid protein genes of human papillomavirus type 16.

Authors:  P Pushko; T Sasagawa; J Cuzick; L Crawford
Journal:  J Gen Virol       Date:  1994-04       Impact factor: 3.891

7.  Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.

Authors:  R C Rose; W Bonnez; R C Reichman; R L Garcea
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies.

Authors:  M E Hagensee; J J Carter; G C Wipf; D A Galloway
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

9.  Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.

Authors:  B Nonnenmacher; N L Hubbert; R Kirnbauer; K V Shah; N Muñoz; F X Bosch; S de Sanjosé; R Viscidi; D R Lowy; J T Schiller
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

10.  Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical neoplasias.

Authors:  T Sasagawa; M Inoue; O Tanizawa; M Yutsudo; A Hakura
Journal:  Jpn J Cancer Res       Date:  1992-07
View more
  3 in total

1.  Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Authors:  Mayumi Nakagawa; Raphael Viscidi; Ian Deshmukh; Maria Da Costa; Joel M Palefsky; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.

Authors:  Alberto Monroy-García; Miguel A Gómez-Lim; Benny Weiss-Steider; Georgina Paz-de la Rosa; Jorge Hernández-Montes; Karyna Pérez-Saldaña; Yessica S Tapia-Guerrero; Mariel E Toledo-Guzmán; Edelmiro Santiago-Osorio; Héctor I Sanchez-Peña; María de Lourdes Mora-García
Journal:  Virol J       Date:  2011-02-09       Impact factor: 4.099

Review 3.  Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers.

Authors:  Zhen Dong; Renjian Hu; Yan Du; Li Tan; Lin Li; Juan Du; Longchang Bai; Yingkang Ma; Hongjuan Cui
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.